Approved May 1996
Ocuflox has been approved for the treatment of corneal ulcers. The approval also supports the broader use of Ocuflox, which is already indicated for the treatment of bacterial conjunctivitis. Ocuflox is part of a class of anti-bacterial agents called fluoroquinolones that exhibit a broad spectrum of activity, low resistance, and favorable side-effects profile.
The Ocuflox drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.